IP Library Granted Patent US 11,352,366
Granted Patent B2
US 11,352,366 · App. 17/392,949 · Granted Jun 7, 2022

2-aminoquinazolinone derivative

Inventor: Tomoyuki Furuta (Osaka, JP)
Assignee: SUMITOMO DAINIPPON PHARMA CO., LTD.
C07D491/107C07D239/95C07D401/04C07D403/04C07D403/12C07D405/12
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,352,366
App. No.
17/392,949
Granted
Jun 7, 2022
Kind
B2
Abstract

The present invention provides a 2-aminoquinazolinone derivative. The present invention is a compound represented by formula (1) [wherein X 1 represents CR or N, X 2 represents CR 2 or N, X 3 represents CR 3 or N, Y represents an optionally substituted C 6-10 aryl or optionally substituted 6 to 10-membered heteroaryl, Z represents an optionally substituted C 6-10 aryl, R A represents a hydrogen atom, halogen, cyano, optionally substituted C 1-6 alkyl sulfonyl, optionally substituted C 1-6 alkyl, or optionally substituted C 1-6 alkoxy, and R 1 , R 2 , and R 3 independently represent a hydrogen atom, halogen, optionally substituted C 1-6 alkyl, or optionally substituted C 1-6 alkoxy] or a pharmaceutically acceptable salt thereof.

Claims (15)

1. A compound selected from:

2-anilino-6-fluoro-3-phenylquinazolin-4(3H)-one,

2-{4-[(azetidin-1-yl)methyl]anilino}-6-chloro-3-phenylquinazolin-4(3H)-one and

6-chloro-2-{4-[(3,3-difluorazetidin-1-yl)methyl]anilino}-3-phenylquinazolin-4(3H)-one or a pharmaceutically acceptable salt thereof.

2. The compound of claim 1 , wherein the compound is 2-anilino-6-fluoro-3-phenylquinazolin-4(3H)-one, or pharmaceutically acceptable salt thereof.

3. The compound of claim 1 , wherein the compound is 2-{4-[(azetidin-1-yl)methyl]anilino}-6-chloro-3-phenylquinazolin-4(3H)-one, or pharmaceutically acceptable salt thereof.

4. The compound of claim 1 , wherein the compound is 6-chloro-2-{4-[(3,3 difluoroazetidin-1-yl)methyl]anilino}-3-phenylquinazolin-4(3H)-one, or pharmaceutically acceptable salt thereof.

5. A pharmaceutical composition comprising an effective amount of the compound or pharmaceutically acceptable salt thereof according to claim 1 .

6. A pharmaceutical composition comprising an effective amount of the compound or pharmaceutically acceptable salt thereof according to claim 1 , and one or more pharmaceutically acceptable excipient.

7. A pharmaceutical composition comprising an effective amount of the compound or pharmaceutically acceptable salt thereof according to claim 2 .

8. A pharmaceutical composition comprising an effective amount of the compound or pharmaceutically acceptable salt thereof according to claim 2 , and one or more pharmaceutically acceptable excipient.

9. A pharmaceutical composition comprising an effective amount of the compound or pharmaceutically acceptable salt thereof according to claim 3 .

10. A pharmaceutical composition comprising an effective amount of the compound or pharmaceutically acceptable salt thereof according to claim 3 , and one or more pharmaceutically acceptable excipient.

11. A pharmaceutical composition comprising an effective amount of the compound or pharmaceutically acceptable salt thereof according to claim 4 .

12. A pharmaceutical composition comprising an effective amount of the compound or pharmaceutically acceptable salt thereof according to claim 4 , and one or more pharmaceutically acceptable excipient.

Assignments (2)
CORRECTIVE ASSIGNMENT TO CORRECT THE THE ERRONEOUS PROPERTY NUMBER PREVIOUSLY RECORDED AT REEL: 059969 FRAME: 0017. ASSIGNOR(S) HEREBY CONFIRMS THE ASSIGNMENT. Recorded Oct 31, 2022
From: SUMITOMO DAINIPPON PHARMA CO., LTD.
To: SUMITOMO PHARMA CO., LTD.
Reel/Frame 062029/0341 →
CHANGE OF NAME Recorded May 12, 2022
From: SUMITOMO DAINIPPON PHARMA CO., LTD.
To: SUMITOMO PHARMA CO., LTD.
Reel/Frame 059969/0017 →
Priority Claims (1)
JP JP2019-158612 · Aug 30, 2019 · national
Continuity (2)
Continuation 17427831
Related Publication 20210380598A1 · Dec 9, 2021